Decreased serum miR-181a is a potential new tool for breast cancer screening

Guo,Li-Juan; Zhang,Qing-Yun

doi:10.3892/ijmm.2012.1021

Decreased serum miR-181a is a potential new tool for breast cancer screening

Authors:
- Li-Juan Guo
- Qing-Yun Zhang
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital and Institute, 100142 Beijing, P.R. China
Published online on: June 11, 2012 https://doi.org/10.3892/ijmm.2012.1021
Pages: 680-686

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) screening is important for early detection, but conventional tumor markers lack the desired sensitivity. Aberrant microRNA (miRNA) expression plays an important role in tumor formation and development. Thus, serum miRNAs represent potential BC biomarkers. microRNA-181a (miR-181a) is deregulated in many types of human cancer and is a key oncogenic regulator, but the relationship between serum miR-181a and BC diagnosis has not been investigated. This study investigated serum miR-181a levels in BC patients and healthy controls and compared the diagnostic value of serum miR-181a as a BC tumor marker with the conventional tumor markers CA153 and CEA. Serum miR-181a and miR-16 (as a control) were quantified by real-time quantitative RT-PCR in 20 plasma samples. The promising results prompted analysis of 227 additional samples. The levels of CA153 and CEA were measured using electrochemiluminescence assays. Median miR-181a levels were significantly lower in patients with BC compared to healthy controls (P=0.001). ROC analysis demonstrated the sensitivity and specificity of miR-181a for BC diagnosis at 70.7 and 59.9%, respectively, whereas the sensitivities of CA153 and CEA were 10.53 and 9.21%. As a tumor marker, serum miR-181a expressed a higher level of sensitivity [55.28% (68/123)] in the early stage of BC diagnosis (ductal carcinoma in situ, TNM I and II) than the CA153 and CEA markers (8.13 and 7.32%, respectively). There were no significant associations between miR-181a levels and other clinicopathological parameters. These results suggest that serum miR-181a may represent a novel biomarker for primary BC as well as for early stage BC diagnosis. In combination with other markers, serum miR-181a may improve the sensitivity of BC screening.

View Figures

View References

1.	A JemalF BrayMM CenterJ FerlayE WardD FormanGlobal cancer statisticsCA Cancer J Clin616990201110.3322/caac.20107
2.	C DeSantisR SiegelP BandiA JemalBreast cancer statisticsCA Cancer J Clin61409418201110.3322/caac.20134
3.	R SiegelE WardO BrawleyA JemalCancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deathsCA Cancer J Clin61212236201110.3322/caac.2012121685461
4.	S YektaIH ShihDP BartelMicroRNA-directed cleavage of HOXB8 mRNAScience304594596200410.1126/science.109743415105502
5.	DP BartelMicroRNAs: genomics, biogenesis, mechanism, and functionCell116281297200410.1016/S0092-8674(04)00045-514744438
6.	S BaggaJ BrachtS HunterRegulation by let-7 and lin-4 microRNAs results in target mRNA degradationCell122553563200510.1016/j.cell.2005.07.03116122423
7.	BJ ReinhartFJ SlackM BassonThe 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegansNature403901906200010.1038/3500260710706289
8.	PH OlsenV AmbrosThe lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking lin-14 protein synthesis after the initiation of translationDev Biol216671680199910642801
9.	HH ZhangXJ WangGX LiE YangNM YangDetection of let-7a microRNA by real-time PCR in gastric carcinomaWorld J Gastroenterol1328832888200717569129
10.	W WuM SunGM ZouJ ChenMicroRNA and cancer: Current status and prospectiveInt J Cancer120953960200710.1002/ijc.2245417163415
11.	R VisoneF PetroccaCM CroceMicro-RNAs in gastrointestinal and liver diseaseGastroenterology13518661869200810.1053/j.gastro.2008.10.07419013167
12.	MV IorioP CasaliniC PiovanMicroRNA-205 regulates HER3 in human breast cancerCancer Res6921952200200910.1158/0008-5472.CAN-08-292019276373
13.	R GarzonCE HeaphyV HavelangeMicroRNA 29b functions in acute myeloid leukemiaBlood11453315341200910.1182/blood-2009-03-21193819850741
14.	A CimminoGA CalinM FabbrimiR-15 and miR-16 induce apoptosis by targeting BCL2Proc Natl Acad Sci USA1021394413949200510.1073/pnas.050665410216166262
15.	KA O’DonnellEA WentzelKI ZellerCV DangJT Mendellc-Myc-regulated microRNAs modulate E2F1 expressionNature435839843200515944709
16.	CD JohnsonA Esquela-KerscherG StefaniThe let-7 microRNA represses cell proliferation pathways in human cellsCancer Res6777137722200710.1158/0008-5472.CAN-07-108317699775
17.	J BrenneckeA StarkRB RussellSM CohenPrinciples of microRNA-target recognitionPLoS Biol3e85200510.1371/journal.pbio.003008515723116
18.	BP LewisCB BurgeDP BartelConserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targetsCell1201520200510.1016/j.cell.2004.12.03515652477
19.	GA CalinC SevignaniCD DumitruHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancersProc Natl Acad Sci USA10129993004200410.1073/pnas.030732310114973191
20.	MA CortezGA CalinMicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseasesExpert Opin Biol Ther9703711200910.1517/1471259090293288919426115
21.	W GaoY YuH CaoDeregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosisBiomed Pharmacother64399408201010.1016/j.biopha.2010.01.01820363096
22.	KH ShinSD BaeHS HongRH KimMK KangNH ParkmiR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-rasBiochem Biophys Res Comm404896902201110.1016/j.bbrc.2010.12.05521167132
23.	SD BhattacharyaJ GarrisonMicro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell linesSurgery148292297201010.1016/j.surg.2010.05.00720576283
24.	SFM HauslerA KellerPA ChandranWhole blood-derived miRNA profiles as potential new tools for ovarian cancer screeningBr J Cancer103693700201010.1038/sj.bjc.660583320683447
25.	AJ LoweryN MillerRE McNeillMJ KerinMicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer managementClin Cancer Res14360365200810.1158/1078-0432.CCR-07-099218223209
26.	PS MitchellRK ParkinEM KrohCirculating microRNAs as stable blood-based markers for cancer detectionProc Natl Acad Sci USA1051051310518200810.1073/pnas.080454910518663219
27.	Z HuangD HuangS NiZ PengW ShengX DuPlasma microRNAs are promising novel biomarkers for early detection of colorectal cancerInt J Cancer127118126201010.1002/ijc.2500719876917
28.	H ZhaoJ ShenL MedicoA pilot study of circulating miRNAs as potential biomarkers of early stage breast cancerPLoS One5e13735201010.1371/journal.pone.001373521060830
29.	EK NgWW ChongH JinDifferential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screeningGut5813751381200910.1136/gut.2008.16781719201770
30.	M TanakaK OikawaM TakanashiDown-regulation of miR-92 in human plasma is a novel marker for acute leukemia patientsPLoS One4e5532200910.1371/journal.pone.000553219440243
31.	J WangJ ChenP ChangMicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of diseaseCancer Prev Res2807813200910.1158/1940-6207.CAPR-09-009419723895
32.	KE ResnickH AlderJP HaganDL RichardsonCM CroceDE CohnThe detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformGynecol Oncol1125559200910.1016/j.ygyno.2008.08.03618954897
33.	M SagawaY SaitoS FujimuraRI LinnoilaK-ras point mutation occurs in the early stage of carcinogenesis in lung cancerBr J Cancer77720723199810.1038/bjc.1998.1189514049
34.	SD BhattacharyaJ GarrisonH GuoMicro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell linesSurgery148291297201010.1016/j.surg.2010.05.00720576283
35.	L ShiZ ChengJ Zhanghsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cellsBrain Res1236185193200810.1016/j.brainres.2008.07.08518710654
36.	F MengR HensonH Wehbe-JanekK GhoshalST JacobT PatelMicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancerGastroenterology133647658200710.1053/j.gastro.2007.05.02217681183
37.	FY MengR HensonM LangInvolvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell linesGastroenterology13021132129200610.1053/j.gastro.2006.02.05716762633
38.	JB WeidhaasI BabarSM NallurMicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapyCancer Res671111111116200710.1158/0008-5472.CAN-07-285818056433